Beta Bionic, Inc. (BBNX)

Beta Bionic Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Net Income	-55.5	-44.1	-64.75
Depreciation & Amortization	2.3	2.09	2.09
Share-Based Compensation	-	5.66	6.1
Other Operating Activities	12.86	3.91	-3.64
Operating Cash Flow	-40.34	-32.45	-60.21
Capital Expenditures	-3.15	-0.4	-0.77
Change in Investments	-	-69.3	-
Other Investing Activities	-40.28	0	0
Investing Cash Flow	-43.42	-69.69	-0.77
Share Issuance / Repurchase	-	101.03	56.78
Financing Cash Flow	-1.27	101.03	56.78
Net Cash Flow	-85.03	-1.11	-4.2
Free Cash Flow	-43.49	-32.85	-60.98
Free Cash Flow Margin	-82.00%	-273.84%	-34067.04%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).